Yazar "Turkon, H." seçeneğine göre listele
Listeleniyor 1 - 7 / 7
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Are Small Adrenal Incidentalomas Solely a Radiological Finding?(Johann Ambrosius Barth Verlag Medizinverlage Heidelberg Gmbh, 2015) Eroglu, M.; Erbag, G.; Turkon, H.; Binnetoglu, E.; Ozkul, F.; Gunes, F.; Sen, H.Objective: The criterium defining the threshold size of adrenal incidentaloma (AI) is a size greater than 1cm diameter. However, data concerning AI1cm in diameter is scant. The aim of this study was to evaluate the function of adrenal masses1cm and to compare them with adrenal masses>1cm. Materials and Methods: The study included 130 consecutive patients with AI (38 and 92 AI at 1cm and >1cm, respectively). The patients were evaluated according to demographic and hormonal characteristics. Results: The prevalence of SCS was 5.3 and 12% in AI1cm and >1cm diameter, respectively. Hyperaldosteronism was found only in patients with >1cm AI. Pheochromocytoma were not found in either group. Patients with >1cm AI had a higher prevalence of SCS and primary hyperaldosteronism than patients with 1cm AI, but the difference was not significant. The prevalence of diabetes and hypertension was high both in non-functional AI with 1cm and >1cm patients and showed no significant difference between the 2 groups. Conclusion: Our study is the first to focus on the clinical and hormonal characteristics of patients with 1cm AI. Those with AI1cm harboured SCS, as was the case for AI>1cm. Similar to AI>1cm, non-functional AI1cm also had a higher prevalence of diabetes and hypertension.Öğe COMPARISON OF BIOMARKERS IN BLOOD AND URINE ACCORDING TO PHENOTYPES IN COPD(Elsevier, 2019) Hunerel, O.; Mutlu, P.; Mirici, N. A.; Cakir, D.; Turkon, H.; Gul, A. H.[Anstract Not Available]Öğe Correlation between Bethatrophin and 25(OH)D Concentrations in a Group of Subjects With Normal and Impaired Glucose Metabolism(Georg Thieme Verlag Kg, 2017) Turkon, H.; Yalcin, H.; Toprak, B.; Demirpence, M.; Yasar, H. Y.; Colak, A.Aim Inducing beta cell replication is a potential therapeutic approach for the treatment of diabetes mellitus. Recently betatrophin was suggested as a novel stimulator of beta cell proliferation in mice but its role in humans remains to be established. We aimed to investigate betatrophin concentration and its association with metabolic parameters in a group of individuals with normal glucose tolerance, pre-diabetes and diabetes mellitus who had not been previously treated. Methods A total of 72 subjects were recruited for this cross sectional study: 23 subjects with normal glucose tolerance (NGT), 22 subjects with prediabetes, and 27 subjects with diabetes mellitus (DM). Circulating betatrophin concentration, 75 g oral glucose tolerance test, fasting insulin, glycosylated hemoglobin, 25hydroxy vitamin D and HOMA IR were measured. Results The difference in betatrophin values did not reach statistical significance between the 3 groups [NGT: 206 (176-297) pg/mL, Prediabetes: 232 (181-254) pg/mL, DM: 245 (205-526) pg/mL, p = 0.078]. Betatrophin was negatively significantly correlated with BMI and positively significantly correlated with 25(OH) vitD (p = 0.043 and p = 0.001 respectively). Multivariate linear regression showed that 25(OH) vitD (beta = 0.440 p = 0.001) and fasting glucose (beta = 0.003 p = 0.038) were variables associated with betatrophin concentration (R2 = 0.251). Conclusions In a group of subjects ranging from those with normal glucose tolerance to newly diagnosed diabetes, we found that 25(OH) D and fasting glucose were factors associated with serum betatrophin concentration.Öğe Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?(Springer, 2019) Demirpence, M.; Guler, A.; Yilmaz, H.; Sayin, A.; Pekcevik, Y.; Turkon, H.; Colak, A.PurposeAcromegaly is a rare disorder existed in the result of overproduction of growth hormone (GH). The disorder is associated with increased cardiovascular risk factors and metabolic abnormalities. Urotensin II (UII), a secreted vasoactive peptide hormone, belonging somatostatin superfamily, plays an essential role in atherosclerosis and glucose metabolism. The aim of this study was to ascertain whether circulating UII levels are altered in subjects with acromegaly, and to describe the relationship between UII and hormonal or cardiometabolic parameters. MethodsThis cross-sectional study included 41 subjects with active acromegaly, 28 subjects with controlled acromegaly, and 37 age- and BMI-matched controls without acromegaly. Hormonal and metabolic features of the subjects as well as carotid intima media thickness (cIMT) and epicardial fat thickness (EFT) were defined. Circulation of UII levels was determined via ELISA.ResultsBoth active and controlled acromegalic subjects showed a significant elevation of circulating levels of UII with respect to controls. There was no remarkable difference in circulating levels of UII between active and controlled acromegalic groups. Both cIMT and EFT were remarkably increased in acromegaly subjects comparing to controls. UII positively correlated with cIMT, EFT, BMI, and HOMA-IR. There was no correlation between UII and GH, insulin-like growth factor-1. According to the results obtained from regression models, UII levels independently predicted cIMT and EFT.ConclusionElevated UII levels are associated with severity of cardiovascular risk factors including cIMT and EFT in acromegalic subjects.Öğe Prognostic value of depression, anxiety disorders and inflammatory markers in patients with heart failure(Wiley, 2019) Gazi, Emine; Karaahmet, E.; Turkon, H.; Barutcu, A.[Anstract Not Available]Öğe Relationship between betatrophin levels and metabolic parameters in patients with polycystic ovary syndrome(C M B Assoc, 2016) Erbag, G.; Eroglu, M.; Turkon, H.; Sen, H.; Binnetoglu, E.; Aylanc, N.; Asik, M.To evaluate the status of serum betatrophin levels and potential relations between metabolic parameters and betatrophin levels in patients with polycystic ovary syndrome. We included patients newly diagnosed with PCOS in our study. Fifty-seven female patients (30 patients with PCOS and 27 healthy control subjects) were enrolled in this study. Serum betatrophin levels were measured using a betatrophin enzyme-linked immunosorbent assay kit. Insulin resistance was calculated using the homeostasis model of the assessment-insulin resistance index formula. The betatrophin level was 1538,85 ng/L in the patient group and 2440,46 ng/L in the control group, and the difference was statistically significant (p=0.003). A significantly negative correlation was found between betatrophin level and insulin, HOMA-IR, and BMI. Betatrophin levels in patients with PCOS are lower than those without PCOS and inversely related to insulin resistance.Öğe Serum irisin levels in patients with morbid obesity(Wiley-Blackwell, 2016) Colak, A.; Yalcin, H.; Toprak, B.; Turkon, H.; Demirpence, M.; Yilmaz, H.; Bozkurt, U.[Anstract Not Available]
